Financial Performance

Camlin Fine Sciences Limited reported mixed financial results for FY25-26. On a standalone basis, the company reported a net loss of ₹329.66 crore, significantly improved from the ₹763.11 crore loss in the previous year. Revenue from operations declined 5.48% to ₹837.92 crore. However, on a consolidated basis, the company reported a net profit of ₹27.63 crore, marking a substantial turnaround from the ₹139.05 crore loss in FY25, with consolidated revenue growing 5.81% to ₹1,723.31 crore.

Strategic Acquisition

The company completed the strategic acquisition of 83.82% stake in Vinpai SA, France, an ingredient-tech company specializing in functional ingredients from algae, plants, minerals and fibers. The acquisition was executed through a share swap arrangement where Camlin issued 41.06 lakh equity shares at ₹247.69 per share (including premium of ₹246.69) aggregating ₹101.71 crore. The total investment in Vinpai reached ₹147.34 crore including subsequent conversion of EUR 3.3 million convertible bonds.

Capital Structure & Financing

A rights issue raised ₹224.68 crore in FY25, with proceeds utilized for debt repayment (₹169.05 crore) and general corporate purposes (₹54.94 crore). The company's credit rating was revised downward with long-term rating reduced to IND BBB- from IND BBB and short-term rating to IND A3 from IND A3+ by India Ratings and Research.

Exceptional Items & Provisions

Significant exceptional items impacted FY26 results including ₹114.59 crore provision for doubtful loan and interest receivable, ₹22.22 crore impact from new labour codes on retirement benefits, ₹76.34 crore loss from fire at two subsidiaries, and ₹40.58 crore Vinpai acquisition costs. Discontinued operations, including the liquidation of CFS Europe S.p.A., contributed a gain of ₹102.91 crore from derecognition of assets and liabilities.

Subsidiary Updates

Several subsidiary changes occurred including CFS Europe S.p.A. entering judicial liquidation proceedings, CFS Pahang Asia Pte. Ltd. being struck off, and Solentus North America Inc. dissolved. The company also invested ₹54.99 crore for a 49% stake in Clean Max Sundarban Private Limited for captive hybrid solar/wind power plant.

Corporate Governance & AGM

The Board recommended re-appointment of directors Harsha Raghavan and Jens Van Nieuwenborgh and ratified cost auditor remuneration for FY26-27. The 33rd Annual General Meeting is scheduled for August 11, 2026 through video conferencing with remote e-voting from August 8-10, 2026. No dividend was recommended for FY25-26 due to losses and current economic scenario.

Forward Outlook

The company remains focused on portfolio expansion of its Xtendra®, NaSure®, and Ezential® platforms, domestic market expansion in poultry and aquaculture businesses, and export growth leveraging trade dynamics. Strategic priorities for the Americas region include specialty solutions, animal nutrition growth, and biodiesel expansion.